Baker Bros. Advisors’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Baker Bros. Advisors’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,080,000	Closed	-$20.9M	–	92
2023 Q4	$20.9M	Buy	2,080,000 +1,080,000	+108%	+$4.9M	0.24%	38
2023 Q3	$2.88M	Hold	1,000,000	–	–	0.02%	77
2023 Q2	$3.81M	Buy	+1,000,000	New	+$2.8M	0.02%	79

Baker Bros. Advisors's GRCL Position: Q1 2024 in Review

Baker Bros. Advisors sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2024, closing a stake of 2,080,000 shares — an estimated $20.9M sold.

Baker Bros. Advisors first reported a position in GRCL in Q2 2023 and held it in 3 quarters. The position peaked at $20.9M in Q4 2023. 0 funds tracked by Wall St. Rank hold GRCL as of Q1 2024.

Baker Bros. Advisors reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2024 after selling out during the quarter.
Baker Bros. Advisors sold 2,080,000 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2024, an estimated $20.9M.
Baker Bros. Advisors first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q2 2023 and held it in 3 quarters.
Baker Bros. Advisors's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $20.9M in Q4 2023.
0 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2024.

Based on Baker Bros. Advisors's 13F filing for Q1 2024, filed 15 May 2024.